A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662
PHASE1CompletedINTERVENTIONAL
Enrollment
13
Participants
Timeline
Start Date
August 31, 2012
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
Conditions
Healthy Volunteer, Down Syndrome
Interventions
DRUG
RG1662
Single oral dose
DRUG
placebo
Single oral dose
Trial Locations (1)
NW10 7EW
London
All Listed Sponsors
lead
Hoffmann-La Roche
INDUSTRY
NCT01667367 - A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662 | Biotech Hunter | Biotech Hunter